Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

News provided by Eli Lilly and Company Jun 16, 2025, 6:45 AM ET With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month ...

A Chinese-developed weight loss shot looked almost as good as Eli Lilly’s megablockbuster Zepbound in late-stage trial results rolled out Tuesday morning, in one more sign of the impending ...

The company pledged to soon make its highest marketed Zepbound strengths, the drug's 12.5 mg and 15 mg doses, available in single-dose vials for $499 a month through its LillyDirect self-pay ...

Lilly has shared few details about eloralintide before now, because it’s still in the early stages of testing. It’s part of a class of drugs that mimic the hormone amylin, which slows ...

However, Lilly’s GLP-1 products have shown better results in clinical studies. In an earlier head-to-head study, LLY’s Zepbound has shown superior weight loss than NVO’s Wegovy.